Yazar "Nalkıran, İhsan" için listeleme
-
Association of paraoxonase-1 L55M and Q192R polymorphisms with PCOS risk and potential risk factors for atherosclerosis
Nalkıran, Hatice Sevim; Şahin, Serap Baydur; Ayaz, Teslime; Nalkıran, İhsan; Güzel, Ali İrfan; Eldeş, Tuğba; Yıldız, Yasin (Future Medicine Ltd, 2019)Aim: To examine the PON1-L55M and-Q192R polymorphisms for polycystic ovary syndrome (PCOS) risk in relation with atherosclerosis risk markers. Methods: Blood samples were collected from 203 women (PCOS [n = 151], control ... -
Comparison of DNA isolation methods from mammalian sperm cells and development of a new protocol
Nalkıran, Hatice Sevim; Nalkıran, İhsan; Rakıcı, Sema Yılmaz; Tümkaya, Levent; Güzel, Ali İrfan (Effect Publishing Agency ( EPA ), 2021)Sperm DNA tightly packed with protamines makes the DNA isolation procedure from sperm cells long and laborious. Cell lysis is also a challenging step because of the disulfide bonds-rich membranes of the sperm cells. In ... -
Determination of gene expression and serum levels of MnSOD and GPX1 in colorectal cancer
Nalkıran, İhsan; Turan, Saime; Arıkan, Soykan; Kahraman, Özlem Timirci; Acar, Leyla; Yaylım, İlhan; Ergen, Arzu (Int Inst Anticancer Research, 2015)Background/Aim: Oxidative stress plays a role on the development of colorectal cancer. Manganese superoxide disnzutase (MnSOD) and glutathione peroxidase I (GPXI) are crucial in regulating oxidative balance and its ... -
An electrochemical immuno-cytosensor modified with nanofibers for the determination of a carcinoembryonic antigen
Yıldızbakan, Zehra; Altuntaş, Derya Bal; Nalkıran, Hatice Sevim; Aslan, Sema; Mamuk, Atilla Eren; Koçak, Çağdaş; Kurt, Şeymanur; Nalkıran, İhsan; Yener, Çiğdem; Ünlü, C. Gökhan (Springer, 2024)In this study, La0.25Fe0.75FeO3 (PNp)perovskite nanoparticle was synthesized using the sol–gel method. PNp-coated polyacrylonitrile (PAN) nanofibers were prepared by electrospinning on the pencil graphite electrode (PGE) ... -
Genetic variations in OLR1 gene associated with PCOS and atherosclerotic risk factors
Şahin, Serap Baydur; Nalkıran, İhsan; Ayaz, Teslime; Güzel, Ali İrfan; Eldeş, Tuğba; Calapoğlu, Tuğba; Nalkıran, Hatice Sevim (Sage Publications, 2023)Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age. The aim of this study was to investigate the association of oxidized low-density lipoprotein receptor 1 (OLR1) gene variations ... -
Investigation of a glioblastoma risk-associated SNP of the PTPRB Gene in familial glioblastoma
Sevim Nalkıran, Hatice; Rakıcı, Sema Yılmaz; Nalkıran, İhsan (Turkiye Klinikleri, 2023)Objective: To investigate the association of the single nucleotide polymorphism (SNP) rs2252784 in the protein tyrosine phos-phatase receptor type B (PTPRB) gene with familial glioblastoma multiforme (GBM). Material and ... -
Investigation of Gpx1 gene expression, serum Gpx1 and selenium levels on colorectal cancer
İplik, Elif Sinem; Nalkıran, İhsan; Turan, Saime; Arıkan, Soykan; Yaylım, İlhan; Ergen, Hayriye Arzu (Marmara Üniversitesi, Sağlık Bilimleri Enstitüsü, 2019)Objective: Colorectal cancer is one of the first lines when examined the death cause of cancer. It is well known that family history, and racial and ethnic background and daily life are related with colorectal cancer and ... -
Prognostic importance of PD-L1 expression in bladder cancer patients
Durur, Sümeyye; Uzun, Hakkı; Bedir, Recep; Nalkıran, İhsan; Nalkıran, Hatice Sevim (Wolters Kluwer Medknow Publications, 2023)Background: PD-L1/PD-1 molecules are known as important mediators in immune-escape mechanisms of tumors. PD-L1 is highly expressed in various malignancies, including bladder cancer. However, the prognostic value of PD-L1 ... -
Targeting the anaphase-promoting complex/cyclosome (APC/C) enhanced antiproliferative and apoptotic response in bladder cancer
Nalkıran, Hatice Sevim; Yıldız, Dilara Akcora; Saydam, Faruk; Güzel, Ali İrfan; Nalkıran, İhsan (Elsevier, 2023)Improving the chemotherapy sensitivity of bladder cancer is a current clinical challenge. It is critical to seek out effective combination therapies that include low doses of cisplatin due to its dose-limiting toxicity. ...
